TICKERNERD
Menu
IMUXIMUXHealthcare · Biotechnology

IMUX Stock Forecast: Immunic, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$16
−3.14% on the day

The 11 Wall Street analysts covering Immunic, Inc. hold a median 12-month price target of $29 — +77.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 15 Aug 2026 — in the lower half.

Market cap
$219.1M
Ticker Nerd rank
40 / 100
Median analyst target
$29
Analysts covering
11
Total return, dividends reinvested
1W
+12.3%
1M
+9.3%
YTD
+200.7%
1Y
+75.1%
From 52W high
−3.1%
From 52W low
+214.9%
$5
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMUX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Immunic, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
81
Momentum
80
Size
67
Revisions
57
Accruals
47
Growth
40
Issuance
36
Value
19
Quality
18

Volatility (81): The share price has been relatively steady.

Quality (18): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IMUX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMUX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26IMUXHigh $85Median $29Low $19

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $19Median $29High $85

The green dot is the last close — the median target sits +77.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 May 2026B. Riley SecuritiesMaintainsBuy$40 → $27
30 Apr 2026HC Wainwright & Co.MaintainsBuy—
17 Apr 2026StifelInitiatesBuy—
15 Apr 2026D. Boral CapitalDowngradeHold—
24 Mar 2026GuggenheimInitiatesBuy—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
13 Feb 2026D. Boral CapitalMaintainsBuy—
9 Feb 2026HC Wainwright & Co.ReiteratesBuy—
7 Jan 2026D. Boral CapitalMaintainsBuy—
14 Nov 2025HC Wainwright & Co.MaintainsBuy—
13 Nov 2025D. Boral CapitalMaintainsBuy—
29 Sept 2025Chardan CapitalInitiatesBuy—
26 Sept 2025HC Wainwright & Co.ReiteratesBuy—
25 Sept 2025D. Boral CapitalMaintainsBuy—
8 Aug 2025D. Boral CapitalMaintainsBuy—
25 June 2025D. Boral CapitalMaintainsBuy—
5 June 2025D. Boral CapitalMaintainsBuy—
29 May 2025D. Boral CapitalMaintainsBuy—
23 May 2025B. Riley SecuritiesReiteratesBuy—
1 May 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMUX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

IMUX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Immunic, Inc. (IMUX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.6×

Cheaper than 86% of US stocks

Price / sales
—
Price / book
1.4×

Cheaper than 58% of US stocks

EV / EBITDA
−0.5×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−138.2%

Higher than 10% of US stocks

Return on assets
−66.8%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

IMUX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMUXImmunic, Inc.$219.1M
40
TNXPTonix Pharmaceuticals Holding Corp.$218.0M
21
RNAAtrium Therapeutics, Inc.$219.7M
6
ANTXAN2 Therapeutics, Inc.$215.3M
74
ALECAlector, Inc.$213.9M
41
NERVMinerva Neurosciences, Inc.$213.4M
31
IVVDInvivyd, Inc.$212.4M
19

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Immunic, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMUX news & analysis

Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?

Zacks Investment Research · 13 Aug 2026positive

Zacks reported that the mean of analysts' price targets for Immunic (IMUX) suggests a 163% upside, and noted that strong agreement among analysts in raising earnings estimates indicates a potential upward move.

Why it matters — An IMUX watcher would care because the article highlights analyst consensus pointing to significant upside and positive earnings estimate revisions for the stock.

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Proactive Investors · 11 Aug 2026positive

Immunic reported Q2 results and confirmed its Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing multiple sclerosis remain on track to deliver top-line data by the end of 2026. The company is also expanding its leadership team in preparation for potential regulatory filings and commercialization.

Why it matters — IMUX watchers would care because the company's lead drug candidate is advancing toward a key Phase 3 data readout, a significant milestone that could determine the drug's regulatory and commercial path in multiple sclerosis.

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

PRNewsWire · 11 Aug 2026positive

Immunic reported its second quarter 2026 financial results and provided a corporate update, announcing key executive appointments including CEO, CMO, and a new board chair to support clinical development and NDA/commercial readiness. The pivotal Phase 3 ENSURE trials of vidofludimus calcium in relapsing multiple sclerosis remain on track with top-line data expected by end of 2026, and preparations continue for a Phase 3 trial in progressive multiple sclerosis planned for later this year.

Why it matters — The update affirms progress on Immunic's late-stage vidofludimus calcium program across multiple sclerosis indications and signals strengthening of its leadership as it approaches key clinical milestones.

Immunic Appoints Elena Ridloff to Board of Directors

PRNewsWire · 10 Aug 2026positive

Immunic, Inc. announced the appointment of Elena Ridloff, CFA, to its Board of Directors, effective August 6, 2026. Ms. Ridloff, who holds more than two decades of biopharmaceutical experience in financial strategy, corporate growth, and capital markets execution, joins as the company approaches its pivotal Phase 3 ENSURE readout in relapsing multiple sclerosis, as well as potential regulatory filings and commercialization.

Why it matters — The addition of financial, capital markets, and commercial leadership to the board strengthens Immunic as it nears a pivotal Phase 3 data readout and potential regulatory and commercialization milestones.

FAQ

Frequently asked questions about IMUX stock

What is the IMUX stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Immunic, Inc. have a median 12-month price target of $29, with estimates ranging from $19 to $85. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMUX stock a buy right now?

Of the 11 analysts covering Immunic, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immunic, Inc. 40 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMUX?

As at 15 Aug 2026, Immunic, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (81 of 100).

Will IMUX stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +77.5% from the last close, and Ticker Nerd's factor model ranks Immunic, Inc. 40 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMUX stock forecast for 2030?

No analyst covering Immunic, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMUX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $85 over the next 12 months.

How has IMUX stock performed over the past year?

Immunic, Inc. returned +75.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Immunic, Inc. do?

Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing selective oral therapies for immune-mediated and neurologic diseases.

What is the latest news on IMUX?

The most recent item we track (Zacks Investment Research, 13 Aug 2026): "Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?". Zacks reported that the mean of analysts' price targets for Immunic (IMUX) suggests a 163% upside, and noted that strong agreement among analysts in raising earnings estimates indicates a potential upward move.

Company

About Immunic, Inc.

Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing selective oral therapies for immune-mediated and neurologic diseases. Headquartered in New York, United States, the company concentrates on small-molecule drugs designed to modulate specific immune and inflammatory pathways while aiming to maintain convenient oral administration for patients. Its pipeline targets chronic inflammatory conditions and neuroinflammatory disorders where dysregulated immune responses play a central role. Immunic, Inc. works across key therapeutic areas such as multiple sclerosis and other autoimmune-related indications, positioning its candidates as potential alternatives or complements to injectable or infused treatments. In the broader healthcare and biotechnology market, the company contributes to innovation in immunology by advancing differentiated compounds through clinical development, collaborating with investigators, and engaging with regulatory bodies. Through this focus, Immunic, Inc. plays a role in the ongoing shift toward more targeted and patient-friendly approaches to managing complex immune-driven diseases.

CEO Mr. Erik Lundgren · 92 employees · United States · https://imux.com